Successful Primary Infliximab Treatment of Orofacial Crohn's Disease without Gastrointestinal Manifestation.
10.4166/kjg.2012.59.6.437
- Author:
Bo Yong JUNG
1
;
Suck Ho LEE
;
Seung Kyu CHUNG
;
Chang Kyun LEE
;
Tae Hoon LEE
;
Il Kwun CHUNG
;
Sun Joo KIM
;
Hyun Deuk CHO
Author Information
1. Department of Internal Medicine, Cheonan Hospital, Soon Chun Hyang University College of Medicine, Cheonan, Korea. ygun99@hanmail.net
- Publication Type:Case Reports ; English Abstract
- Keywords:
Orofacial Crohn's disease;
Oral ulcer, infliximab
- MeSH:
6-Mercaptopurine/analogs & derivatives/therapeutic use;
Aged;
Anti-Inflammatory Agents/*therapeutic use;
Antibodies, Monoclonal/*therapeutic use;
Crohn Disease/diagnosis/*drug therapy;
Female;
Gastrointestinal Diseases/pathology;
Humans;
Immunosuppressive Agents/therapeutic use;
Oral Ulcer/diagnosis
- From:The Korean Journal of Gastroenterology
2012;59(6):437-440
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Crohn's disease is a chronic inflammatory bowel disease that can involve the whole gastrointestinal tract. The orofacial manifestation of Crohn's disease, which is rare, can develop irrespective of intestinal involvement. These orofacial lesions are often misdiagnosed as simple oral ulcers. Corticosteroids are the mainstay of therapy for orofacial Crohn's disease. However, infliximab, the chimeric monoclonal antibody to tumor necrosis factor-alpha, is now considered as a primary treatment because of the disease's relatively high rate of steroid resistance. We present a case of deep oral ulcer and periorbital swelling in a 65-year-old woman. She was diagnosed with intestinal Crohn's disease 7 years ago, which was in remission after treatment with an immunosuppressive agent (azathioprine). The patient was given the diagnosed with orofacial Crohn's disease and successfully treated with infliximab.
